Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors.
Drug screening
Malignant peripheral nerve sheath tumor
Primary culture
Xenograft
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
08
2019
accepted:
29
01
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
27
2
2020
Statut:
epublish
Résumé
Malignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of soft-tissue sarcoma, derived from a peripheral branch or the sheath of the sciatic nerve, brachial plexus, or sacral plexus. The clinical outcomes for MPNST patients with unresectable or metastatic tumors are dismal, and novel therapeutic strategies are required. Although patient-derived cancer cell lines are vital for basic research and preclinical studies, few MPNST cell lines are available from public cell banks. Therefore, the aim of this study was to establish cancer cell lines derived from MPNST patients. We used tumor tissues from five patients with MPNSTs, including one derived from a rare bone tissue MPNST. The tumor tissues were obtained at the time of surgery and were immediately processed to establish cell lines. A patient-derived xenograft was also established when a sufficient amount of tumor tissue was available. The characterization of established cells was performed with respect to cell proliferation, spheroid formation, and invasion. The mutation status of actionable genes was monitored by NCC Oncopanel, by which the mutation of 114 genes was assessed by next-generation sequencing. The response to anti-cancer agents, including anti-cancer drugs approved for the treatment of other malignancies was investigated in the established cell lines. We established five cell lines (NCC-MPNST1-C1, NCC-MPNST2-C1, NCC-MPNST3-C1, NCC-MPNST4-C1, and NCC-MPNST5-C1) from the original tumors, and also established patient-derived xenografts (PDXs) from which one cell line (NCC-MPNST3-X2-C1) was produced. The established MPNST cell lines proliferated continuously and formed spheroids while exhibiting distinct invasion abilities. The cell lines had typical mutations in the actionable genes, and the mutation profiles differed among the cell lines. The responsiveness to examined anti-cancer agents differed among cell lines; while the presence of an actionable gene mutation did not correspond with the response to the anticipated anti-cancer agents. The established cell lines exhibit various characteristics, including proliferation and invasion potential. In addition, they had different mutation profiles and response to the anti-cancer agents. These observations suggest that the established cell lines will be useful for future research on MPNSTs.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of soft-tissue sarcoma, derived from a peripheral branch or the sheath of the sciatic nerve, brachial plexus, or sacral plexus. The clinical outcomes for MPNST patients with unresectable or metastatic tumors are dismal, and novel therapeutic strategies are required. Although patient-derived cancer cell lines are vital for basic research and preclinical studies, few MPNST cell lines are available from public cell banks. Therefore, the aim of this study was to establish cancer cell lines derived from MPNST patients.
METHODS
METHODS
We used tumor tissues from five patients with MPNSTs, including one derived from a rare bone tissue MPNST. The tumor tissues were obtained at the time of surgery and were immediately processed to establish cell lines. A patient-derived xenograft was also established when a sufficient amount of tumor tissue was available. The characterization of established cells was performed with respect to cell proliferation, spheroid formation, and invasion. The mutation status of actionable genes was monitored by NCC Oncopanel, by which the mutation of 114 genes was assessed by next-generation sequencing. The response to anti-cancer agents, including anti-cancer drugs approved for the treatment of other malignancies was investigated in the established cell lines.
RESULTS
RESULTS
We established five cell lines (NCC-MPNST1-C1, NCC-MPNST2-C1, NCC-MPNST3-C1, NCC-MPNST4-C1, and NCC-MPNST5-C1) from the original tumors, and also established patient-derived xenografts (PDXs) from which one cell line (NCC-MPNST3-X2-C1) was produced. The established MPNST cell lines proliferated continuously and formed spheroids while exhibiting distinct invasion abilities. The cell lines had typical mutations in the actionable genes, and the mutation profiles differed among the cell lines. The responsiveness to examined anti-cancer agents differed among cell lines; while the presence of an actionable gene mutation did not correspond with the response to the anticipated anti-cancer agents.
CONCLUSION
CONCLUSIONS
The established cell lines exhibit various characteristics, including proliferation and invasion potential. In addition, they had different mutation profiles and response to the anti-cancer agents. These observations suggest that the established cell lines will be useful for future research on MPNSTs.
Identifiants
pubmed: 32099531
doi: 10.1186/s12935-020-1128-z
pii: 1128
pmc: PMC7031935
doi:
Types de publication
Journal Article
Langues
eng
Pagination
58Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests. The funders had no role in the design of the study, collection, analyses, or interpretation of data, writing of the manuscript, or in the decision to publish the results.
Références
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Cancer Res Treat. 2017 Jul;49(3):717-726
pubmed: 28052660
Neuro Oncol. 2009 Dec;11(6):725-36
pubmed: 19246520
Nat Genet. 2014 Nov;46(11):1170-2
pubmed: 25305755
J Clin Oncol. 2009 Jul 1;27(19):3133-40
pubmed: 19451436
Lancet Neurol. 2007 Apr;6(4):340-51
pubmed: 17362838
Nature. 2014 Oct 9;514(7521):247-51
pubmed: 25119042
Genome Med. 2018 Jun 7;10(1):44
pubmed: 29880027
Cells. 2019 Feb 13;8(2):
pubmed: 30781855
Ann Oncol. 2016 Oct;27(10):1855-60
pubmed: 27502708
J Med Genet. 2002 May;39(5):311-4
pubmed: 12011145
Cancer Res. 2002 Mar 1;62(5):1573-7
pubmed: 11894862
J Clin Oncol. 1996 May;14(5):1679-89
pubmed: 8622088
Genes Chromosomes Cancer. 2017 May;56(5):421-426
pubmed: 28124441
Am J Pathol. 2016 Mar;186(3):464-77
pubmed: 26740486
Annu Rev Pathol. 2007;2:191-216
pubmed: 18039098
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Cancer Sci. 2019 Apr;110(4):1480-1490
pubmed: 30742731
Cancer Chemother Pharmacol. 1989;24(3):148-54
pubmed: 2544306
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Cancer. 1986 May 15;57(10):2006-21
pubmed: 3082508
J Biomol Tech. 2018 Jul;29(2):25-38
pubmed: 29805321
Assay Drug Dev Technol. 2004 Aug;2(4):363-72
pubmed: 15357917
Nature. 2019 Apr;568(7753):511-516
pubmed: 30971826
Cancer Discov. 2013 Jun;3(6):674-89
pubmed: 23535903
Nat Protoc. 2009;4(3):309-24
pubmed: 19214182
Am J Pathol. 1999 Dec;155(6):1879-84
pubmed: 10595918
Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50
pubmed: 20952405
Nat Genet. 2014 Nov;46(11):1227-32
pubmed: 25240281
Neuro Oncol. 2013 Feb;15(2):135-47
pubmed: 23161774
Clin Cancer Res. 2017 Nov 15;23(22):6934-6945
pubmed: 28814433
Int J Surg Pathol. 2017 Oct;25(7):629-634
pubmed: 28508686
Neurosurg Clin N Am. 2008 Oct;19(4):533-43, v
pubmed: 19010279
Mol Cancer Ther. 2009 May;8(5):1157-68
pubmed: 19417153
J Clin Oncol. 2009 Jul 1;27(19):3148-53
pubmed: 19451433
Pharmacol Ther. 2016 Jul;163:94-108
pubmed: 27063403
J Neuropathol Exp Neurol. 2010 Jan;69(1):16-26
pubmed: 20010306
Surg Oncol Clin N Am. 2003 Apr;12(2):355-68
pubmed: 12916459
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669